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Abstract
Background: This study was conducted in order to determine the use of aspirin and to assess the
achievement of therapeutic targets in diabetic patients according to primary (PP) or secondary
prevention (SP).
Methods: This is a retrospective, observational study including patients ≥18 years with diabetes
mellitus followed in four primary care centers. Measurements included demographics, use of aspirin
and/or anticoagulant drugs, co-morbidities, clinical parameters and proportion of patient at
therapeutic target (TT). Descriptive statistics, chi-square test and logistic regression model were
used for significance.
Results: A total of 4,140 patients were analyzed, 79.1% (95% confidence intervals [CI]: 77.7–
80.5%) in PP and 20.9% (95% CI: 18.2–23.7%) in SP. Mean age was 64.1 (13.8) years, and 49.3% of
patient were men (PP: 46.3, SP: 60.7, p = 0.001). Aspirin was prescribed routinely in 20.8% (95%
CI: 19.4–22.2%) in PP and 60.8% (95% CI: 57.6–64.0%) in SP. Proportion of patient at TT was 48.0%
for blood pressure and 59.8% for cholesterol. Use of aspirin was associated to increased age [OR
= 1.01 (95% CI: 1.00–1.02); p = 0.011], cardiovascular-risk factors [OR = 1.14 (95% CI: 1.03–1.27);
p = 0.013], LDL-C [OR = 1.42 (95% CI: 1.06–1.88); p = 0.017] and higher glycated hemoglobin [OR
= 1.51 (95% CI: 1.22–1.89); p = 0.000] were covariates associated to the use of aspirin in PP.
Conclusion: Treatment with aspirin is underused for PP in patients with diabetes mellitus in
Primary Care. Achievement of TT should be improved.
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Background
Arterial hypertension, hypercholesterolemia, smoking,
obesity, lack of physical activity and diabetes mellitus rep-
resent the main modifiable risk factors for the occurrence
of cardiovascular diseases in developed countries [1].
Patients with diabetes mellitus have a cardiovascular risk
two to four times higher than the general population.
Complications attributable to atherosclerosis are respon-
sible for 70–80% of all deaths in diabetic patients and
account for more than 75% of all hospital admissions,
causing high rates of disability and health resource utiliza-
tion [2]. There is currently a clear trend to an increased
prevalence, due both to the progressive aging of the pop-
ulation and to the increased frequency of sedentary habits
and obesity.
This situation makes institution of drug measures for pri-
mary and secondary prevention in patients with cardio-
vascular disease (CVD) a primary objective. The American
Diabetes Association [3] (ADA) recommends use of
antiaggregants (low-dose acetyl salicylic acid [ASA], 75–
325 mg/day) in all diabetic patients with established CVD
(secondary prevention) and in those with no CVD who
have a high risk of cardiovascular events (primary preven-
tion) or are over 40 years of age, provided there is no doc-
umented contraindication, such as allergy to salicylates,
bleeding risk, anticoagulant therapy, recent gastrointesti-
nal bleeding, active liver disease, or the age (to prevent
Reye syndrome). These recommendations are based on
three studies (ETDRS [4], HOT [5], and the Physicians'
Health Study [6] showing that this treatment decreases the
incidence of myocardial infarction in people with diabe-
tes. Two of these studies are included in the meta-analysis
of the US Preventive Services Task Force [7], which con-
firmed the decrease in the incidence of myocardial infarc-
tion, but found no significant differences in mortality
reduction. In this regard, the American Heart Association
[8] and the results reported by several meta-analyses
[9,10] recommend preventive treatment with ASA in peo-
ple with a 10-year risk higher than 10%. Despite the fact
that various Spanish scientific societies (such as the Cata-
lan Societies of Diabetes, Neurology, Cardiology, Family
and Community Medicine, etc.) also support the start of
ASA therapy as one of the main cost-effective measures,
the scant evidence reported in our setting [11-13] suggest
that it is underused. Additional studies conducted in other
countries further support the consistency of these results
[14-18].
The rationale of the study was to review to what extent
these recommendations/guidelines, which are evidence
base medicine, are implemented in real world standard
condition of care in a primary care setting in Spain. Then,
the purpose of this study was to determine the use of ASA
for cardiovascular prevention in patients with diabetes
mellitus at several health care centers under standard clin-
ical practice conditions, and to ascertain the extent to
which some therapeutic control objectives are achieved in
primary care setting.
Methods
Study design and data extraction
A retrospective, observational study was conducted based
on the medical records of patients monitored on an out-
patient basis and under standard clinical practice condi-
tions. The study population consisted of people of either
sex attending four primary care centers managed by
Badalona Serveis Assistencials SA. All patients older than
18 years diagnosed of diabetes mellitus according to the
criteria established by the ADA [3] and seen at the center
over the past two years (January 2004 and December
2005) were enrolled in the study. Patients with a doubtful
diagnosis and patients in whom onset of the disease had
occurred less than 3 months before were excluded from
the study (n = 186).
Variables recorded included age, sex, social security status
(active worker, retired), primary care center identification,
time (months) since initial diagnosis of the disease,
number of annual visits attended according to the proto-
col or clinical practice guideline for cardiovascular risk of
the centers, number of cardiovascular risk factors, treat-
ment prescribed, and regular use of ASA or other oral
antiaggregant and/or anticoagulant drugs (including trif-
lusal, clopidogrel, ticlopidine, warfarin and acenocou-
marol). Aspirin regular use by a patient was established
when a physician prescribed aspirin for more than 8
months per year. Clinical diagnoses or comorbidities
associated to diabetes mellitus were obtained from the
International Classification of Primary Care (ICPC-2)
[19]. Non-repeated events seen in the population consid-
ered included arterial hypertension (K86, K87), hypercho-
lesterolemia (T93: partial), active smoker (P17), obesity
(T82); presence of CVD: ischemic heart disease (K74: car-
diac ischemia with angina, K75: acute myocardial infarc-
tion, K76: coronary ischemia), cerebrovascular accident
(K90, K91: transient cerebral ischemia), and peripheral
artery disease (K92: intermittent claudicating, Raynaud
syndrome, arterial stenosis or embolism); and other co-
morbidities: congestive heart failure (K77), renal failure
(U99), liver failure (D97), chronic obstructive pulmonary
disease (R95: chronic airflow obstruction), depressive
syndrome (P76), and benign prostate hypertrophy (Y87).
Information was obtained from the computerized clinical
records. Legal regulations on data confidentiality were
complied with at all times.
Measurements
The clinical parameters measured included the cardiovas-
cular risk index (Framingham calculation adapted for pri-BMC Family Practice 2007, 8:60 http://www.biomedcentral.com/1471-2296/8/60
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mary care), body mass index (BMI < 29, kg/m2), systolic
(SBP, mmHg) and diastolic blood pressure (DBP,
mmHg), total cholesterol (mg/dL), low density lipopro-
tein cholesterol fraction (LDL-C, obtained by the Friede-
wald formula [20]), high density lipoprotein cholesterol
fraction (HDL-C), and glycated hemoglobin (HbA1c).
Some of the established recommendations [3,21] for
blood pressure (SBP/DBP < 130/80 mmHg), and LDL-C
(<100 mg/dL), see Table 1. Besides, we followed modified
criterion to adapt them to a real clinical practice condi-
tions: glycated hemoglobin (<6.5%), total cholesterol
(<200 mg/dL) and body mass index (BMI < 29, kg/m2),
they were considered as adequate follow-up or target
objectives.
The last measurement obtained during 2005 was consid-
ered in all cases.
Statistical methods
Data depuration and database refining from mistake or
wrong records were carried out in order to obtain good
data to run statistical analyses. Personal data were blinded
before analysis in order to guarantee proper anonymity of
patient's data in accordance with present local regulations
with data management and processing. Descriptive statis-
tics (mean, standard deviation and 95% confidence inter-
val) and testing of Gaussian distribution by means of the
Kolmogorov-Smirnov test were performed for descriptive
purposes. Bivariate analysis using t-test, Man-Whitney test
or Chi2, as appropriated, were applied to compare main
patients' characteristics between primary and secondary
prevention. To test for homogeneity of centers, we used an
analysis of variance (ANOVA) or Chi2 tests.
Multiple logistic regression models (enter step procedure)
were carried out in the total sample, and in the subgroups
according with type of prevention. The use of ASA was the
dependent variable, and all significant variables observed
in the bivariate analysis were incorporated into the mod-
els as independent factors. These included mean age
(years), sex (male), active workers, time since disease
onset (months), number of visits in the annual cardiovas-
cular risk protocol, presence of a cardiovascular history,
hypercholesterolemia and active smoking, and achieve-
ment of the therapeutic control objectives (dichotomic
variables): blood pressure (<130/80 mmHg), total choles-
terol (<200 mg/dL), LDL-C (<100 mg/dL) and HbA1c
(<6.5%). SPSS version 14.0 for Windows software was
used, and a value of p < 0.05 was established as the signif-
icant level.
Ethical considerations
The World Medical Association has developed the Decla-
ration of Helsinki as a statement of ethical principles to
provide guidance to physicians and other participants in
medical research involving human subjects. The authors
show that in the elaboration of the study the basic princi-
ples for all medical research and the confidentiality of the
data have been respected marked by the law.
Results
The number of patients with established diagnosis of dia-
betes mellitus was 4,140 (crude prevalence: 6.4% of the
total population), 79.1% (CI: 77.7–80.5%) in primary
prevention and 20.9% (CI: 18.2–23.7%) in secondary
prevention. Overall, by December 2004, 14.6% of
patients followed diet therapy, while 55.2% were receiv-
ing oral antidiabetics, 9.7% oral antidiabetics plus insu-
lin, and 20.5% insulin alone.
Table 2 shows the general characteristics of the studied
series, the cardiovascular history, and the therapeutic con-
trol objectives in patients with diabetes mellitus by pri-
mary care center. No differences were seen between
Table 1: Therapeutic targets in prevention and treatment of cardiovascular disease in diabetes.
Metabolic control (normal blood glucose)
- Acceptable: blood glucose < 140 mg/dl and HbA1c < 7%
- Ideal: basal blood glucose < 110 mg/dl and HbA1c < 6%
Lipid normalization
- TC < 170 mg/dl and TG < 150 mg/dl
- LDL-C < 100 mg/dl (or non-HDL cholesterol < 130 mg/dl)
- HDL-C > 40 mg/dl.
Blood pressure control (BP < 130/80 mmHg)
Smoking cessation Weight loss (normal weight)
- Acceptable: BMI < 27 kg/m2
- Ideal: BMI < 25 kg/m2
Frequent aerobic physical exercise
Other measures: antiaggregants are under study to show their value in diabetes (use of low-dose ASA is recommended in some subjects with high 
cardiovascular risk)
HbA1c: glycated hemoglobin; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; BMI: body mass index; ASA: 
acetyl salicylic acid. Source: "Grupo de Trabajo Diabetes mellitus. Diabetes mellitus y riesgo cardiovascular. Recomendaciones del Grupo de 
Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes. Clin Invest Arterioscl 2004;16:74–8".BMC Family Practice 2007, 8:60 http://www.biomedcentral.com/1471-2296/8/60
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centers in cardiovascular events (range, 20.0–22.2%) or
cardiovascular history (except for arterial hypertension;
range, 49.4–55.8%; p = 0.002), and the percentages seen
for hypercholesterolemia, active smoking, and obesity
showed a certain homogeneity. The greatest variability
between centers was seen in percentage of use of ASA
(ranging from 20.0 to 35.3%; p < 0.001), mean patient
age (ranging from 62.2 [14.2] to 65.5 [13.5]; p < 0.001),
and particularly achievement of therapeutic target objec-
tives. Thus, target blood pressure (<130/80 mmHg) was
achieved in 37.4–57.6% of patients (p = 0.002); target
total cholesterol (<200 mg/dL) in 42.1–50.7% of patients
(p < 0.001); and target LDL-C (<100 mg/dL) in 13.5% to
21.7% of cases (p = 0.000).
Distribution of the study variables by type of prevention
(primary or secondary) is shown in Table 3. Mean patient
age was 64.1 (13.8) years, and the values for patients in
primary and secondary prevention were 62.3 (14.1) years
and 70.9 (10.0) years respectively (p = 0.000). There was
a 2.8% primary prevention (PP) patients aged less than 30
years, as compared to none in the secondary prevention
(SP) group. Males accounted for 49.3% of the population
(PP: 46.3; SP: 60.7; p = 0.000). Of all patients, 29.2% (CI:
27.8%–30.6%) was prescribed in ASA, 20.8% (CI:
19.4%–22.2%) in PP and 60.8% (CI: 57.6%–64.0% in SP;
10.5% of patients were routinely prescribed some other
oral antiaggregant or anticoagulant (PP: 5.1%; SP: 30.9%;
p = 0.000). In SP, blood pressure (55.9%) and hypercho-
lesterolemia (47.5%) were most prevalent in the history,
and the conditions where better therapeutic control objec-
tives were achieved (48.0% and 59.8% respectively; p =
0.000). The distribution of the number of cardiovascular
risk factors associated to patients with diabetes mellitus
(primary or secondary prevention) is shown in Figure 1. It
should be noted that most diabetic patients with no pres-
ence of CVD have 2 (35.8%) or 3 (29.5%) cardiovascular
risk factors.
The final regression logistic model (Table 4) showed that
patients with controlled-total-cholesterol were signifi-
cantly associated to the use of ASA in secondary preven-
tion; OR = 1.50; CI: 1.02–2.21; p = 0.039. However,
patients on primary prevention, were more likely to use
ASA when age increases (OR = 1.01; IC: 1.00–1.02; p =
0.011), show a higher number of cardiovascular risk fac-
tors (OR = 1.14; CI: 1.03–1.27; p = 0.013), achieve thera-
peutic LDL-C targets (OR = 1.42; CI: 1.06–1.88; p =
0.017), and get a poor metabolic control of glycated
hemoglobin (OR = 1.51; CI: 1.22–1.89; p = 0.000).
Discussion
Studies on the use of acetyl salicylic acid for primary and
prevention of cardiovascular disease in adult diabetic
patients and their adherence to the recommendations in
clinical practice guidelines are heterogeneous in character
[11-18], [22-24]. It is important to note that the different
methods used for measuring some variables in the
reviewed studies make comparisons difficult and requires
caution when considering the external validity of results.
However, such limitations do not invalidate the current
knowledge obtained from such patients, resulting from
observations under standard clinical practice conditions
in an outpatient setting.
Table 2: General distribution of patients with diabetes mellitus by primary care center (PCC).
Variables PCC-1 n = 978 PCC-2 n = 1,486 PCC-3 n = 902 PCC-4 n = 774 p
CVD (events, %) 22.2 20.7 20.0 21.1 ns
Use of ASA (%) 29.1 35.3 20.0 28.2 0.000
Sex (males, %) 46.9 51.5 46.8 50.9 0.041
Mean age (SD), years 62.2 (14.2) 64.1 (13.5) 65.5 (13.5) 64.9 (13.9) 0.000
CV history
Hypertension 49.4 51.2 55.8 50.0 0.002
Hypercholesterolemia 35.8 39.5 37.7 36.2 ns
Active smoking 21.6 17.7 18.3 17.2 ns
Obesity (BMI < 29) 48.5 46.9 46.4 43.9 ns
Therapeutic targets
BP (<130/80 mmHg) 49.6 37.4 50.1 57.6 0.002
Total cholesterol (<200 mg/dL) 50.6 50.7 41.1 45.0 0.000
LDL-C (<100 mg/dL) 20.6 21.7 13.5 17.1 0.000
Glycated HbA1c (<6.5%) 33.3 34.4 32.0 33.6 ns
Values are given as percentage or mean (SD: standard deviation); p: statistical significance; CVD: cardiovascular disease; ASA: acetyl salicylic acid; 
CV: cardiovascular; BMI: body mass index; BP: blood pressure (mmHg); LDL-C: low density lipoprotein cholesterol (mg/dL); Hb: hemoglobin.BMC Family Practice 2007, 8:60 http://www.biomedcentral.com/1471-2296/8/60
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Although explanations may arise when an attempt is
made to analyze the general characteristics of patients
based on their clinical history (direct correlation between
age and arterial hypertension), some degree of uncertainty
is generally shown in the care process [25], that may pos-
sibly be influenced by the health status of the population
and the different existing clinical practice approaches, ran-
domly distributed among the primary care centers
reviewed.
In our study, ASA was prescribed by 29.2% of diabetic
patients (CI: 27.8–30.6%). However, the proportion
increased to 39.4% when use of other antiaggregant or
anticoagulant drugs was considered. It should be stressed
that in SP the proportion reaches 91.7% of diabetic
patients (as compared to 25.9% in PP). Diabetic patients
with CVD are mostly older men with a longer time since
disease onset and a higher number of associated comor-
bidities (arterial hypertension and hypercholestero-
lemia). Moreover, this group has been subject to a more
extensive follow-up in the scheduled control visits, and
has shown a better achievement of therapeutic goals
(except for glycated hemoglobin). It should be noted that
a history of CVD clearly suggests to the physician and
patient the need for treatment, while the opposite occurs
when there is no such history. While, by definition, dia-
betic patients with no history of cardiovascular disease are
considered "primary prevention" patients, the risk for dia-
betics with no coronary history is in some studies similar
to the risk of post-myocardial infarction non-diabetic
patients [26]. This fact has caused the control objectives
for risk factors in the diabetic population established by
scientific associations to be similar to those recom-
mended for secondary prevention patients. These obser-
vations demonstrate the potential relationship between
monitoring and a better metabolic control [27,28]. An
increased awareness and a more decided action by the
family physician when faced with a diabetic patient in sec-
ondary prevention may also exist [17].
Use of ASA for primary prevention in patients with diabe-
tes mellitus is considered in elderly diabetics with several
cardiovascular risk factors, LDL-C therapeutic objectives,
and poor metabolic control of glycated hemoglobin. In
these patients (with no cardiovascular event), both ASA
use and achievement of control objectives can still be
improved, particularly taking into account that most pri-
mary prevention patients meet criteria for antiaggregant
therapy [3,11,22]. Patients and/or healthcare profession-
als may possibly see regular use of ASA as a non-relevant
or second level treatment, as discussed by some authors
[16,17] and demonstrated in our study. This suggests that
patients with diabetes are not treated as a function of risk,
but of the presence of CVD and the degree of metabolic
control achieved.
The results obtained, when compared to national studies
[11-13], generally show some differences in the character-
istics of the diabetic patients studied, possibly attributable
to the population profile used, but the rates of ASA under-
used are similar. Other consulted series show incremental
percentages over the years, but lower than desirable values
[14-17,24]. Therapeutic control objectives were achieved
in similar or slightly higher percentages as compared to
other series reviewed [28,29]. It is paradoxical that while
various renowned scientific associations [3,8,21] recom-
mend use of ASA or other antiaggregants for primary pre-
vention in diabetic patients older than 40 years, or
patients under 21 years of age having some associated risk
factor, such advice is not followed in clinical practice. But
the most important thing is that a CVD (often angina or
infarction) is not prevented [11]. In this regard, the cost of
prevention of a cardiovascular event with ASA treatment
would be much lower than the costs resulting from hospi-
talization and sequels, not to speak of the social and per-
sonal burden for these patients [2,11].
The efficacy of ASA in clinical trials [4-9,30] contrasts with
various pathophysiological studies that would explain
why patients with diabetes mellitus may be more resistant
to the potential benefits of the drug. Some authors postu-
late that response to preventive ASA treatment could be
different in diabetic patients for several reasons [31].
These would include the fact that diabetes may be a form
of resistance to ASA or to low doses of ASA; platelets of
these patients could be activated by various mechanisms
that would lead to thrombosis, or also because the inflam-
matory stimuli present in diabetic patients could induce a
cyclooxygenase-2 enzyme poorly sensitive to ASA. It has
also been postulated that hyperglycemia could generate a
Distribution of the number of cardiovascular risk factors  (CVRFs) associated to patients in primary or secondary pre- vention Figure 1
Distribution of the number of cardiovascular risk factors 
(CVRFs) associated to patients in primary or secondary pre-
vention.BMC Family Practice 2007, 8:60 http://www.biomedcentral.com/1471-2296/8/60
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significant amount of endoperoxides and thromboxan
that would counteract the action of cyclooxygenases [32].
Some limitations of the study require caution in the gen-
eralization of the results. Such limitations include the ret-
rospective design of the study, the lack of clinical results
in coordination with other care levels (care continuum),
and the reasons given for contraindication or intolerance
to the drugs, and the lack of measure of ASA with medici-
nal products excluded from or not financed by the
National Health System. The study sample may not be
representative of the general primary care population in
Spain. However, our results should be interpreted with
caution, as further research supporting these results
should be conducted in larger patient populations under
standard clinical practice conditions. Moreover, the
potential specific contraindications for ASA therapy could
not be established in our study.
However, the organizational model and clinical action
protocols [31] of centers such as the ones participating in
the study are very similar, and we agree with several
authors [11,12,14] on the need that scientific associations
and the healthcare administration design approaches
aimed at increasing information and training of health-
care personnel in effective cardiovascular prevention
measures, particularly in patients who have not developed
any cardiovascular event. The results obtained should be
Table 3: General characteristics of patients with diabetes mellitus by type of cardiovascular prevention (primary, secondary).
Characteristics Primary n = 3,273 Secondary n = 867 Total n = 4,140 p
Mean age (SD), years 62.3 (14.1) 70.9 (10.0) 64.1 (13.8) 0.000
Sex (males, %) 46.3 60.7 49.3 0.000
SS status (active, %) 37.4 11.2 31.9 0.000
Time since diagnosis (SD), months 43.2 (37.5) 52.6 (49.1) 45.2 (40.4) 0.000
Follow-up per protocol (SD), visits 3.9 (3.2) 4.4 (3.5) 4.0 (3.3) 0.000
CV history
Arterial hypertension 49.2 55.9 50.6 0.002
Hypercholesterolemia 34.9 47.5 37.6 0.001
Active smoking 19.3 16.0 18.9 0.026
Obesity (BMI < 29) 47.0 45.2 46.6 ns
Other co-morbidities
Heart failure 2.4 8.1 3.6 0.000
Renal failure 1.0 3.2 1.5 0.000
Liver failure 2.8 3.9 3.0 ns
COPD 4.8 12.9 6.5 0.000
Depressive syndrome 14.2 14.6 14.3 ns
Prostatic hypertrophy 4.3 11.1 5.7 0.000
Treatment
Acetyl salicylic acid 20.8 60.8 29.2
Other antiaggregants, OACs 5.1 30.9 10.5 0.000
Clinical parameters
Body mass index (SD) 30.3 (5.3) 29.9 (4.9) 30.2 (5.2) ns
Systolic blood pressure (SD) 135.3 (17.2) 135.4 (17.9) 135.4 (17.4) ns
Diastolic blood pressure (SD) 78.1 (9.4) 75.7 (9.0) 77.5 (9.3) 0.000
Total cholesterol (SD) 206.9 (41.3) 192.9 (39.9) 203.9 (41.4) 0.000
LDL-C (SD) 133.7 (35.4) 123.7 (35.5) 131.6 (35.6) 0.000
Glycated hemoglobin A1c (SD) 7.2 (1.5) 7.4 (1.4) 7.3 (1.5) 0.014
CVR index (SD) 21.1 (9.1) 25.2 (9.9) 22.1 (9.3) 0.000
Therapeutic targets
BP (<130/80 mmHg) 46.1 48.0 46.5 ns
Total cholesterol (<200 mg/dL) 44.1 59.8 47.5 0.000
LDL-C (<100 mg/dL) 16.5 26.9 18.7 0.000
Glycated hemoglobin A1c (<6.5%) 35.2 27.2 33.4 0.001
Values are given as percentage or mean (SD: standard deviation); p: statistical significance; SS: social security; CV: cardiovascular; OACs: oral 
anticoagulants; CVR: cardiovascular risk; BP: blood pressure (mmHg); LDL-C: low density lipoprotein cholesterol (mg/dL); COPD: chronic 
obstructive pulmonary disease.BMC Family Practice 2007, 8:60 http://www.biomedcentral.com/1471-2296/8/60
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of use when considering, based on the available evidence
[3,33], whether treatment should be started with ASA or
other antiaggregant, when indicated, as it seems obvious
that treatment with low-dose ASA is one of the most favo-
rable cost-effective measures in cardiovascular prevention
in diabetic patients [3,22,34-37]. Future research in dia-
betic patients should explore monitoring of preventive
measures, effectiveness of the optimum recommended
doses [38], or the specific reasons for poor patient compli-
ance.
Conclusion
In our study treatment with ASA was underused for pri-
mary cardiovascular prevention in patients with diabetes
mellitus. Achievement of the established therapeutic
objectives should be improved. New representative stud-
ies under standard clinical practice conditions would be
required.
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